Armed with positive results in two phase 3 trials, MSD is poised to be the first drugmaker to file for approval of an oral PCSK9 inhibitor for lowering cholesterol. Top-line results from the CORALreef ...

MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial. The new data ...

Polarean's FDA cleared coil achieves important milestone, expanding clinical reach Polarean Imaging plc (AIM: POLX), a commercial-stage medical imaging technology leader in functional Magnetic ...

You're hunched over the engine with your wrist painfully contorted, wishing you were Mr. Fantastic. You've finally removed broken spark plug number four and then the intrusive thought hits. "Should I ...

Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors' opinions or evaluations. If your checking account is charging you too many fees or ...

To attract new customers, many banks often offer sign-up bonuses. For checking accounts, making a minimum deposit or setting up direct deposit can mean a bonus of at least $100. We compared dozens of ...

Mike Cetera is the editor in chief for Forbes Marketplace U.S. Mike has written and edited articles about mortgages, savings accounts, CD rates and credit cards for more than a decade. Prior to ...

A well-picked business checking account can make a positive impact on the financial operations of your business. And since each business has unique needs, it pays to take your time and compare ...

A lipase test is a blood test that measures the level of a digestive enzyme called lipase in your blood. It may also be referred to as a serum lipase or LPS. What is lipase? Your doctor might order a ...

Psychology Today's online self-tests are intended for informational purposes only and are not diagnostic tools. Psychology Today does not capture or store personally identifiable information, and your ...

The UK Government is investing £60m ($78.76m) to push pharma and biotech to use alternative preclinical models in a pull back from animal testing. UK Science Minister Lord Vallance has given the ...